Background
Ocugen investors brought a putative securities class action against the pharmaceutical company and its CEO, Shankar Musunari, under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. They alleged that Ocugen made misleading statements about its financial results, internal controls, Sarbanes-Oxley certifications, and accounting for its collaboration agreement with CanSinoBIO.
In April 2024, Ocugen announced that it would restate fifteen quarters of financial statements, from the first quarter of 2020 through the third quarter of 2023, because those statements were materially misstated and its internal controls over financial reporting had a material weakness. The announcement concerned accounting for estimated costs under a collaboration agreement and was followed by a 10.38% one-day stock-price decline.
The district court dismissed the amended complaint with prejudice. Relying on prior Third Circuit decisions, it held that the April 2024 disclosure was immaterial as a matter of law because Ocugen’s stock price recovered to its pre-disclosure level within two trading days.
The Court’s Holding
The Third Circuit vacated and remanded. It abrogated the portions of its prior decisions establishing the Oran-Burlington rule, which treated negligible stock-price movement after a corrective disclosure as conclusively establishing immateriality. Supreme Court precedent requires a fact-specific inquiry into whether information would have significantly altered the total mix available to reasonable investors when making investment decisions, the court held.
The court agreed that Ocugen’s August 2023 disclosures regarding the firing of its CFO and delayed quarterly report were not actionable. The investors had not alleged a duty requiring Ocugen to disclose that the CFO allegedly refused to sign the report, and silence without a duty to disclose is not misleading under Rule 10b-5.
But the district court improperly allowed the former categorical materiality rule to end its analysis of the remaining alleged misstatements. On remand, it must assess the alleged financial, internal-control, SOX, and CanSinoBIO statements under the total-mix standard and, if necessary, evaluate scienter. The court also vacated dismissal of the Section 20(a) control-person claim.
Key Takeaways
- A prompt stock-price recovery after a corrective disclosure does not conclusively establish that an earlier statement was immaterial.
- Materiality under Rule 10b-5 is a fact-specific inquiry focused on information available to a reasonable investor at the time of the investment decision.
- A “Big R” restatement does not automatically establish materiality; courts must examine what the restatement reveals about the prior disclosures.
Why It Matters
The decision eliminates a Third Circuit bright-line rule that had allowed defendants to defeat materiality based solely on post-disclosure stock-price behavior. Securities-fraud pleadings in the circuit must instead be assessed in context, including the nature and magnitude of the alleged accounting errors and their significance to investors.
The ruling also distinguishes materiality from loss causation: a court may not limit its materiality review to statements identified as corrective disclosures merely because plaintiffs tie their losses to those disclosures.